WHO gives Inventiva's IVA337 generic name 'lanifibranor'

French biopharma firm Inventiva today announced that the World Health Organization (WHO) has granted it the international non-proprietary name (INN, or generic name) lanifibranor for IVA337, its leading drug candidate, currently is in Phase IIb development for both systemic sclerosis (SSc) and non-alcoholic steatohepatitis (NASH).